modelSodiumSelenite
Extends from Pharmacolibrary.Drugs.ATC.B.B05XA20.
Information
| name: | SodiumSelenite | |
| ATC code: | B05XA20 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 100 | mg |
| volume of distribution: | 12 | L |
| clearance: | 0.5 | L/h |
| other parameters in model implementation | ||
Sodium selenite is an inorganic form of selenium, an essential trace element important for various metabolic processes, antioxidant defense (via the glutathione peroxidase pathway), and thyroid hormone metabolism. Sodium selenite is used for selenium supplementation in total parenteral nutrition, in the prevention and treatment of selenium deficiency in adults and children, and has been investigated as an adjunct in cancer and sepsis therapy. It is an approved pharmaceutical form of selenium supplementation.
Pharmacokinetics
Estimated pharmacokinetic parameters for sodium selenite in adults, as directly published PK parameters for sodium selenite are scarce. Values are extrapolated from published clinical studies using intravenous sodium selenite in adult patients, including intensive care and oncology settings.
References
Manzanares, W, et al., & Heyland, DK (2015). Pharmaconutrition with selenium in critically ill patients: what do we know?. Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition 30(1) 34–43. DOI:10.1177/0884533614561794 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25524883
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)